FDA’s Rosebraugh Commends Ads Addressing Conscientious OTC Use
This article was originally published in The Tan Sheet
Drug marketers who communicate that their OTC products should be taken with the same care as prescription drugs are sending the right message, according to Curtis Rosebraugh, MD, deputy director of FDA's Office of Nonprescription Products
You may also be interested in...
FDA OTC head Charles Ganley, MD, chastised OTC pain reliever marketers for airing comparative DTC ads in the wake of COX-2 safety concerns during a speech May 6 at the Consumer Healthcare Products Association Regulatory & Scientific Conference in Washington, D.C
Recent edgy Tylenol promotions, which contrast sharply with previous traditional ads, reflect a dramatic change in marketing that coincides with McNeil Consumer & Specialty Pharmaceuticals' decision to switch ad agencies last year
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC